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To compare the antileukemic efficacy of idarubicin and mitox-
antrone in elderly patients with acute myeloid leukemia (AML)
and to evaluate the feasibility of autologous transplantation
using PBSC after consolidation in those with a good perform-
ance status, 160 patients (median age 69 years), with AML at
diagnosis, 118 of them with de novo AML and 42 with AML sec-
ondary to myelodysplastic syndrome or toxic exposure (sAML),
received induction treatment with idarubicin, 8 mg/m2/day or
mitoxantrone, 7 mg/m2/day, on days 1, 3, and 5, both combined
with VP-16, 100 mg/m2/day on days 1 to 3 and cytarabine (araC),
100 mg/m2/day, on days 1 to 7. G-CSF, 5 mg/kg/day, was admin-
istered after chemotherapy in patients aged more than 70
years. Patients in complete remission (CR) received one course
of consolidation using the same schedule as for induction
except the araC administration was shortened to 5 days. Some
patients younger than 70 years were then scheduled for auto-
logous stem cell harvest on days 5 to 7 of G-CSF, 5 mg/kg/day,
initiated after hematopoietic recovery from consolidation. Auto-
logous transplantation was performed following an additional
chemotherapy conditioning. Ninety-five patients (59%) achi-
eved CR, without significant difference between the idarubicin
(56% CR) and mitoxantrone (63% CR) group. There was also
no significant difference in CR rate between de novo AML (63%)
and secondary AML (55%) (P = 0.12). Patients aged ,70 years
had 67% CR, while patients aged >70 years had 49% (P = 0.02).
There was no significant difference in the duration of aplasia
between the two arms. Median time to neutrophil recovery was
22 days in patients who received G-CSF following induction
and 27 days in patients who did not (P = 0.006). Severe extra-
hematologic toxicities of induction did not differ between the
two arms and included sepsis (39%), diarrhea (13%), hyperbili-
rubinemia (8%), hemorrhage (6%) and vomiting (6%). Overall,
14 patients (9%), died from toxicity of induction. First consoli-
dation was administered in 74 patients of whom seven (9%)
died from toxicity. Nineteen patients have received transplan-
tation. Median time to recovery of neutrophils .0.5 · 109/1 was
13 days and of platelets .50 · 109/l 43 days following consoli-
dation. There were two toxic deaths. Median disease-free sur-
vival and survival from time of achieving CR of non trans-
planted patients are 6 and 7 months respectively without
difference between the two arms. Fourteen transplanted
patients relapsed at a median of 5 months post-transplant. We
conclude that this regimen is well tolerated and has a good
efficacy to induce CR, without a significant difference in effi-
cacy and toxicity between idarubicin and mitoxantrone. Inten-
sive postinduction, including transplantation, is feasible; how-
ever, this procedure did not seem to prevent early relapse in
the majority of patients. Neither the high rate of CR nor consoli-
dation nor transplant procedure in a selected group of patients
did translate into improved DFS and/or survival.
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Introduction
It has been shown in a randomized comparison from the
EORTC Leukemia Cooperative Group that intensive chemo-
therapy is beneficial to elderly patients with newly diagnosed
acute myeloid leukemia (AML), leading to significantly longer
survival and similar hospitalization requirements as compared
to palliative treatment alone.1 In the past, most protocols for
induction were based on the combination of conventional-
dose cytarabine (araC) with daunorubicin. A review of 15
studies reported between 1985 and 1992 with a total of 2255
patients older than 60 years with newly diagnosed AML
revealed a median CR rate of 46% (range 28 to 58%) and
toxic death rate of 30% (11 to 48%), median survival was 3
months (1.5 to 9 months) and median CR duration 10.5
months (8 to 16 months).2 Since 1990, some randomized stud-
ies have suggested a superiority of more recent intercalating
agents such as mitoxantrone3,4 or idarubicin5–7 to induce CR
and in one study,6 to reduce the relapse rate. The addition of
VP-16 to an anthracycline-araC regimen during induction and
consolidation has been shown to be beneficial for pro-
longation of CR.8
Postinduction with myeloablative cytotoxic treatment fol-
lowed by bone marrow rescue has been shown to be superior
to non-myeloablative chemotherapy alone for prevention of
relapse in patients younger than 60 years in the large EORTC
LCG-GIMEMA AML-8A trial.9 These results were encouraging
enough to try this approach in older patients. Transplant-
related toxicity might be reduced by using chemotherapy-
based conditioning regimens instead of total body irradiation-
containing regimens.10–12 Furthermore, the use of peripheral
blood stem cells (PBSC) instead of bone marrow cells for
transplantation results in a faster recovery of hematopoiesis
and might decrease aplasia-related complications post-
transplant.13,14
We report here the results of a randomized phase II trial of
idarubicin and mitoxantrone in combination with araC and
VP16 for induction and consolidation therapy in elderly AML,
followed by a pilot feasibility study of autologous PBSC trans-
plantation in selected patients.
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Patients aged more than 60 years, with newly diagnosed de
novo AML or AML secondary to a preceding myelodysplastic
syndrome (MDS) or to toxic exposure were eligible for this
trial, provided they had a good performance status (grade 0,
1 or 2, WHO scale) and no severe organ failure.
During the first year of study, the age-limit for autologous
transplantation was 70 years in selected patients. When this
procedure proved to be safe and feasible, the age limit was
increased to 75 years. All patients gave written informed con-
sent before randomization for induction and consolidation.
AML was diagnosed according to FAB criteria.15 There was
no central pathology review. CR was defined by the criteria
of Ellison according to the CALGB,16 and resistant disease by
the criteria of Preisler.17 Bone marrow was assessed for
response approximately 3 weeks after the end of chemo-
therapy, and every 3–4 months during follow-up. Relapse was
defined as an increasing percentage of blasts in the bone mar-
row exceeding 10% or of blast cells and promyelocytes of
greater than 20% in two bone marrow aspirates assessed at
2 weeks interval if in doubt. Extramedullary relapse must be
confirmed by cytologic and/or histologic examinations.
All participating centers were urged to perform cytogenetics
at least at diagnosis, although this was not mandatory for par-
ticipation. Karyotypes were categorized according to the
classification proposed at the sixth International Workshop on
Chromosomes in Leukemia18 which determined the prognosis
associated with each of the specific abnormalities and
complexity of karyotype in AML.19
Therapeutic regimen
Chemotherapy: Induction therapy included either idarub-
icin, 8 mg/m2/day i.v. on days 1, 3 and 5 or, mitoxantrone,
7 mg/m2/day i.v. on days 1, 3, and 5, according to randomiz-
ation, associated with VP-16, 100 mg/m2/day i.v. on days 1
to 3 and araC, 100 mg/m2/day as a continuous infusion, on
days 1 to 7. The dose of mitoxantrone was reduced by 1 mg
as compared to the dose used in the previous EORTC AML9
study, to avoid potential toxicity induced by the addition of
VP16, because a 15% death rate was observed following
induction in the mitoxantrone arm of the AML9 protocol in
which mitoxantrone 8 mg/m2/day for 3 days was combined
with araC but in the absence of VP16.4 Recombinant human
methionyl-G-CSF from Escherichia coli (filgrastim), 5 mg/
kg/day i.v., was administered starting 1 day after the end of
chemotherapy in all patients aged more than 70 years. Its use
was also allowed in younger patients. Patients in CR after one
or two courses of induction treatment received one additional
course for consolidation, administered as early as possible fol-
lowing hematologic recovery, including the administration of
G-CSF if administered during induction. In consolidation araC
was restricted to 5 days. The time of neutrophil recovery cor-
responds to the time between start of chemotherapy (day 1)
and the day PMN exceeded .0.5 · 109/mm3.
Stem cell transplantation: Patients treated in Lyon or Rome
under the age of 70 years or, between September 1994 and
July 1995, 75 years, with a performance status of 0 or 1 (WHO
scale) were scheduled to undergo intensive conditioning regi-
men followed by autologous stem cell transplantation after
one cycle of consolidation treatment. Peripheral blood stem
cell (PBSC) harvest was performed by two to three aphereses
beginning on day 5 of treatment with G-CSF, 5 mg/kg/day s.c.,
initiated within 2 weeks after hematopoietic recovery from
consolidation. PBSC transplantation was first performed after
conditioning with BCNU, 800 mg/m2 i.v. on day - 3.11 Since
early relapses were observed, patients thereafter were con-
ditioned using busulfan, 4 mg/kg/day on days - 6 to - 3,12 and
subsequently with a more intensive regimen consisting of
BCNU, 800 mg/m2 on day - 6, amsacrine, 150 mg/m2/day,
VP16, 150 mg/m2/day, and araC, 300 mg/m2/day, on days - 4
to - 2 (BAVC).10 G-CSF, 5mg/kg/day, i.v., was administered
after transplantation when neutrophil count dropped below
0.1 · 109/1 until recovery.
Supportive care: Supportive care during induction, con-
solidation and autologous transplantation included the use of
reverse isolation or sterile room, prophylactic red blood cell
and platelet transfusions, antibacterial and antifungal gastro-
intestinal decontamination, and the empirical use of
antibiotics in case the patient became febrile.
Statistical analysis
Characteristics of patient groups were compared using Yates
corrected chi square or two-tailed Fisher’s exact test, when
appropriate, for discrete variable and Mann–Whitney non-
parametric test for continuous variables.
Complete remission rates were compared using Yate’s cor-
rected chi-square or two-tailed Fisher’s exact test. 95% confi-
dence intervals (CI) on proportions of CR patients were calcu-
lated using the exact binomial formula. Survival and DFS
probabilities were calculated using the Kaplan and Meier pro-
duct-limit estimate method.20 Their 95% symmetrical CI limit
was calculated according to Greenwood’s method. DFS was
calculated from the time of obtaining CR. Survival curves were
compared using the log-rank test. For analysis of survival and
DFS, patients undergoing autologous hematopoietic stem cell
transplantation while in first CR were censored at the time of
transplantation. Prognostic factors for CR were studied using
stepwise multiple logistic regression. Prognostic factors for
DFS and overall survival were studied using Cox’s pro-
portional hazard model. Statistical significance was defined as
a two-tailed P value <0.05. The treatment group, and all vari-
ables that tended to be statistically (two-tailed P , 0.1) predic-
tive for CR achievement, DFS or survival in the univariate
analysis were proposed for entry in the mulitivariate models
for prediction of the same endpoint. Quantitative variables
were treated as continuous in these analyses. Goodness of fit
of the models was tested using the likelihood ratio statistics.
All computations were made using BMDP software (BMDP
Statistical Software, Los Angeles, CA, USA).
Results
Patient characteristics
One-hundred and sixty patients entered this trial between
April 1993 and February 1996. One-hundred and eighteen
had de novo AML while 23 had AML secondary to toxic
exposure and 19 resulted from transformation of a previous
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Characteristics Patient group
Idarubicin Mitoxantrone
(n = 80) (n = 80)
Etiology of AML
Primary 61 57
Secondary to toxic exposure 14 9
Transformed primary MDS 5 14
Age (years) 69 (60–83)a 69 (60–81)
Sex (M/F) 37/43 42/38
Organomegalyb (y/n) 22/58 23/57
Hemoglobin (g/l) 88 (41–140) 91 (42–131)
Platelets (· 109/l) 64 (4–994) 69 (4–1262)
WBC (· 109/l) 5.8 (0.5–295) 6.4 (0.6–181)
Blood blasts (%) 27 (0–98) 28 (0–97)











Cytogenetic risk group 2/37/22 0/33/31
(Low/Intermediate/High)d
Serum LDH (m/l; n , 450) 515 (139–8390) 615 (168–4326)
Use of G-CSF 43 46
Autologous transplantation 10 9
aValues are expressed as median (range) unless otherwise indi-
cated.
bhepatomegaly, splenomegaly or extrahematologic involvement.
cTwo cases with ,30% blasts (one FAB M2, one FAB M6).
dLow, t(8;21), t(15;17), abn(16); high, - 5/del(5), - 7/del(7), +8,
11q23, t(9;22), complex abnormalitie intermediate, all others,
including normal karyotypes.18,19 None of the two low risk cyto-
genetic patients had at (15;17).
MDS. Twenty-three patients had AML which could not be
classified according to FAB, although they met FAB criteria
for AML. The patient’s characteristics and treatment by ran-
domization are listed in Table 1. There were significantly
more patients with AML secondary to MDS in the mitoxan-
trone group, however, this was compensated by an excess of
patients with AML secondary to toxic exposure in the idarub-
icin group. Overall, there were no differences between the
two randomized groups that might have influenced the results
of the analysis (P values, see Table 2).
Results of induction
Eighty patients were randomized to each of the two treatment
groups. In approximately 76% of the idarubicin group and
80% of the mitoxantrone group chromosomal analysis was
performed at diagnosis. All patients randomized were
included in the analysis, although four of them (three in the
idarubicin and one in the mitoxantrone group) died early,
within the 7 days of induction treatment (Table 2). There was
no significant difference between the idarubicin and mitoxan-
trone arm, with 56% (CI: 44 to 67%) and 63% (CI: 51 to 73%)
of patients achieving CR, respectively. Remission was not con-
trolled by cytogenetics. Four of five patients in whom a second
Table 2 Efficacy of induction according to treatment arm
Treatment No. of CR Resistant Toxic Early
arm patients (%) disease death deatha
(%) (%) (%)
Idarubicin 80 45 (56)b 27 (34) 5 (6) 3 (4)
Mitoxantrone 80 50 (63)c 20 (25) 9 (11) 1 (1)
P 0.52 0.3 0.4 0.6
Total: 160 95 (59) 47 (39) 14 (9) 4 (3)
De novo 118 74 (63)
AML




aDeath during 7 days of induction chemotherapy.
bIncluding four CR after two induction courses.
cIncluding six CR after two induction courses.
Table 3 Extrahematologic toxicity of first induction
Toxicity Number of grade >3
(number of toxic deaths)
Idarubicin Mitoxantrone
(n = 80) (n = 80)
Fever/infection 33 (4) 30 (4)
Nausea/vomiting 4 5
Diarrhea 12 (1) 9
Mucositis 3 1
Hemorrhage 5 4 (2)
Hyperbilirubinemia 7 6
Hypercreatininemia 0 1
Cardiac disordera 2 3 (1)
aFluid overload (four), lethal second myocardial infarction (one).
course of induction was attempted attained CR in the idarub-
icin group, while six of 10 in the mitoxantrone group did.
Conversely, the proportion of patients with resistant disease
or toxic death did not differ between the two groups (Table
2). Median time to neutrophil recovery above 0.5 · 109/l and
platelet recovery above 50 · 109/l following the first course of
induction was 26 days (range: 10 to 46 days) and 25 days (16
to 57 days), respectively, in patients who received idarubicin,
and 24 days (9 to 40 days) and 25 days (15 to 79 days),
respectively, in patients treated with mitoxantrone, without
significant difference between the two groups of patients.
Median time to neutrophil recovery was 22 days (9 to 46 days)
in patients who received G-CSF and 27 days (13 to 36 days)
in those who did not (P = 0.006). Platelet recovery did not
differ regardless of the use of G-CSF. Severe (WHO grade 3
or more) extra-hematologic toxicities of induction are reported
in Table 3. They did not differ between the two arms. Most
frequently severe toxicities included sepsis (observed in 39%
of all patients), diarrhea (13%), hyperbilirubinemia (8%),
hemorrhage (6%) and vomiting (6%). None of the cardiac tox-
icities observed appeared to be related to the use of idarubicin
or mitoxantrone. Overall, 14 patients (9%), five of them
treated with idarubicin and nine with mitoxantrone, died from
toxicity of induction, mainly due to infection (Table 2).
Factors that were significantly related to failure of achieving
CR in an univariate analysis (Table 4) were age >70 years
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analysis
Factor No. of CR rate (%) P valuea
patients
Age
<70 years 91 61 (67) 0.04
.70 years 69 34 (49)
Previous myelodysplasia
Yes 24 9 (38) 0.02
No 136 87 (63)
Splenomegaly
Yes 21 8 (38) 0.05
No 139 87 (62)
Hemoglobin level
,80 g/l 44 29 (66)
100 g/l 78 39 (50) 0.05
100 g/l 36 26 (72)
Cytogenetic risk groupb
Low 2 2 (100)
Intermediate 70 48 (69) 0.05
High 53 26 (49)
aYates corrected chi square or two-tailed Fischer’s exact test.
bSee legend to Table 1 for risk groups definition.
(P = 0.04), due to a higher toxic death rate in the oldest
patients (14% vs 4%, P = 0.04), preceding myelodysplasia
(P = 0.02), initial splenomegaly (P = 0.05), anemia (P = 0.05),
and the presence of cytogenetic abnormalities known to
account for poor prognosis (see description of cytogenetic
groups in Table 1 legend) (P = 0.05). Of these parameters, age
(P = 0.04), previous myelodysplasia (P = 0.03), splenomegaly
(P = 0.02) and anemia (P = 0.03) remained significantly pre-
dictive of poor prognosis for the achievement of CR in the
multivariate analysis.
Results of post-induction
First consolidation according to the protocol was performed
in 76 patients. Nineteen patients, four in the idarubicin group
and 15 in the mitoxantrone group (P = 0.04) did not receive
this consolidaton. Reasons for not undergoing consolidation
did not differ according to the treatment group and included
excessive toxicity of induction (11 patients), early relapse (two
patients), patient refusal (two patients), loss of follow-up (one
patient) and protocol violation (three patients who received
lower doses of maintenance). Median time to neutrophil
recovery above 0.5 · 109/l and platelet recovery above
50 · 109/l were 23 days (15 to 42 days) and 25 days (16 to
63 days), respectively, in patients who received idarubicin
and 21 days (14 to 49 days) and 22 days (13 to 45 days) in
those treated with mitoxantrone, without significant difference
between the two groups. The most frequent extrahematologic
toxicities due to consolidation were the same as for induction.
Seven patients (9%), four of them treated with idarubicin and
three with mitoxantrone, died from toxicity of consolidation.
Nineteen patients, representing 50% of the 38 age-eligible
patients who received the first course of consolidation in the
two centers performing transplants, have received autologous
stem cell transplantation, one of them from bone marrow and
18 from PBSC. The median time from achieving CR to time
of transplant was 3 months (2–5 months). Reasons for not
undergoing transplantation included include excessive tox-
icity of consolidation precluding stem cell harvest for more
than 3 months (five patients), early relapse, within 3 months
of the end of consolidation (four patients), patient refusal (two
patients), inadequate stem cell harvest (four patients) and
practical reasons (four patients). Median age of transplanted
patients was 69 years (range 61 to 74 years). Pretransplant
conditioning used BCNU in six patients, busulfan in nine and
BAVC in four. Patient were grafted with a median of 7.3
(range: 1.5 to 15) · 108 mononuclear cells/kg containing a
median of 8.3 (3.6 to 127) · 106 CD34+ cells/kg and
29.2 · 104 (5.2 to 150) CFU-GM/kg. Median duration of neu-
trophil recovery above 0.5 · 109/l was 13 days (9 to 21 days)
and of platelet recovery above 50 · 109/l 43 days (9 to 135+
days). Severe, WHO grade 3 or more, toxicities included sep-
sis (eight patients), mucositis (four patients), diarrhea (two
patients), vomiting, bleeding and hyperbilirubinemia (one
patient each). Two patients died, one from sepsis and one
from bleeding. There was no cytogenetic evaluation after
successful transplantation.
At a median follow-up of 21 months, 26 patients ran-
domized to receive idarubicin and who did not undergo auto-
logous transplantation, relapsed after 1 to 29 months in CR
while 27 patients in the mitoxantrone arm have relapsed after
0.5 to 20 months in CR.
Median DFS is 6 months in both arms with 13% (CI: 0 to
26%) and 13% (CI: 1 to 25%) of patients surviving disease-
free 2 years from CR in the two groups respectively
(Figure 1a). Median survival is 7 months in the two arms with
17% (CI: 7 to 27%) and 21% (CI: 11 to 31%) of patients sur-
viving 2 years from diagnosis in the two groups respectively
(Figure 1b). Four patients not undergoing transplantation are
currently alive disease-free in the idarubicin arm while five are
in the mitoxantrone arm. Among the 19 patients who received
autologous transplantation, 14 have relapsed at a median of
5 months (range: 2 to 15 months), three are surviving disease-
free (Figure 2). One of them had received conditioning with
busulfan and two with BAVC. Median DFS after transplan-
tation is 5 months and 2-year DFS is 14% (CI: 0 to 31%).
Factors predictive for short DFS in an univariate analysis
were the presence of adenopathies (P = 0.03), cytogenetic
abnormalities known to be of poor prognosis (P = 0.003), and
hyperbilirubinemia (P = 0.05). High-risk cytogenetic anomal-
ies (P = 0.004), hyperbilirubinemia (P = 0.02) and elevated
serum lactic dehydrogenase (LDH) (P = 0.01) were predictive
of short DFS in the multivariate model. Factors predictive for
short survival in an univariate analysis were advanced age
(P = 0.03), the presence of any organ involvement by the leu-
kemia other than bone marrow and blood (P = 0.02), high
WBC count (P = 0.02) and poor risk cytogenetic abnormalities
(P = 0.02). Advanced age (P = 0.02), high WBC count
(P = 0.03) and poor risk cytogenetic abnormalities were pre-
dictive of short survival in the multivariate analysis. Univariate
and multivariate analyses were performed only for relapse, not
for toxic deaths. This statistical analysis concerns, therefore
not all, but 72 patients.
Discussion
Our study shows the feasibility and efficacy of a chemo-
therapy regimen using adapted doses of new intercalating
agents such as idarubicin and mitoxantrone in association
with VP-16 and araC to induce CR in elderly patients with
newly diagnosed AML, without differences in efficacy or tox-
icity between idarubicin and mitoxantrone. However, num-
bers are too small and the follow-up too short to be able to
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Figure 1 Disease-free survival (a) and survival (b) according to
randomization arm.
Figure 2 Disease-free survival after transplantation of the 19
patients who underwent autologous transplantation.
detect a clinically meaningful difference. Still this is the first
study reported (except for abstracts) of a direct comparison
between these two anthracyclines. The 59% CR rate achieved
in our 160 patients with a median age of 69 years with de
novo or secondary AML compares favorably to that reported
in studies recently published in unselected elderly AML
patients, which ranges from 42% to 55%.4,21–25 The previous
EORTC AML9 and AML 11 studies, which targeted the same
patient population using mitoxantrone or daunorubicin in
combination with standard-dose araC for induction and con-
solidation therapy had an overall CR rate of 42% and 55%
respectively.16,22 Although the overall survival in the present
study is not better, CR rate in our de novo AML patients
was 63%.
The encouraging CR rate observed in our trial might be due
to the use of recent intercalating agents since idarubicin as
well as mitoxantrone have been shown to induce CR more
often than daunorubicin in patients with AML.3–7 A recent
study comparing idarubicin and daunorubicin in patients with
de novo AML older than 55 years showed no difference
between the two drugs, although there were less resistant
patients in the idarubicin arm.26 The contribution of VP16 in
achieving CR is also possible. However, two large ran-
domized studies have shown no increase in CR rate when
VP16 was used,8,27 and the Australian study clearly showed
that VP16 was poorly tolerated in the elderly. Therefore, the
doses of either idarubicin or mitoxantrone were attenuated in
our study. Another reason for the improved CR rate in our
study might be the low treatment-related death rate. The death
rate during aplasia in our 160 patients during induction was
9% while in previous trials it ranged from 15 to 29% in
patients treated with idarubicin combined with araC6,7,26,28
and from 14% to 15% in patients who received mitoxantrone
combined with araC.3,4 Except for the EORTC AML 9 study,4
all these trials used significantly higher doses of mitoxantrone
or idarubicin than our trial. Taken together, these results could
indicate that the addition of VP16 to an intercalating agent
plus araC, allows the dose of intercalating agent to be dimin-
ished and reduces the overall toxicity of this regimen without
impairing the antileukemic efficacy of induction.
Despite a good tolerance of our regimen and the use of G-
CSF in all patients aged >70 years, the toxic death rate was
higher in this patient group. The use of G-CSF during chemo-
therapy-induced aplasia in AML led to a more rapid neutro-
phil recovery (for review see Ref. 29). Also, it has been shown
to increase CR rate in two recent trials in elderly AML. How-
ever, in both trials, this effect appeared related to a decrease
of resistant cases rather than of toxic death and did not result
in longer DFS or survival in G-CSF-treated patients.30,31
Consolidation chemotherapy using reduced dosages of araC
could be administered to most patients in CR. However, seven
toxic deaths were observed. DFS remained short despite the
use of VP16. The addition of VP16 had been decided because
it had been shown to increase DFS in a randomized AML
trial.8 In that study, the effect of VP16 was explained by a
reduction of relapse rate in patients younger than 55 years,
while the relapses in older patients remained unaffected.
Intensive chemotherapy conditioning followed by autolog-
ous stem cell rescue could be administered safely to 50% of
patients having undergone the first consolidation and being
eligible according to their age. The use of autologous stem
cell transplantation is generally restricted to younger patients.
The extension of this procedure to older age groups might be
possible using less intensive conditioning regimens.11,12 Con-
ditioning in 15 of our autografted patients used BCNU or bus-
Intensive induction and post-remission treatment in elderly AML
E Archimbaud et al
848
ulfan alone. They had been previously used as single-agent
conditioning prior to autologous transplantation in glioma
patients11 and in chronic myelocytic leukemia,12 respectively.
Due to frequent relapses following the autograft when these
conditionings were used in our AML patients, we switched to
BAVC, a multidrug schedule which has been already used in
younger AML patients, showing results similar to those achi-
eved with more toxic regimen.10 Nevertheless, early relapses
post-graft still occurred, although we have not autografted a
sufficient number of patients after BAVC conditioning to
precisely assess the relapse rate.
It is a general finding that increasing the intensity of induc-
tion and postinduction in elderly AML patients does not result
in prolongation of CR duration as it has been observed in
younger patients.6,32,33,34 In part, this is due to increased tox-
icity in elderly patients. However, it might also be due to the
high frequency of poor prognostic cytogenetic defects in eld-
erly AML, since intensification of therapy including autolog-
ous or allogeneic transplantation in young patients, is much
less effective in preventing relapse in poor prognostic
cytogenetic subgroups.35,36
In summary, our data are encouraging. However, we realize
their limitations because they are obtained from small sub-
groups of patients, and they may not hold out with longer
follow-up. However, they clearly show the feasibility that
selected patients in an elderly population can tolerate more
aggressive chemotherapy for treating AML.
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